Perspectives on TB/HIV Scale-Up For the Next Ten Years

Amb. Eric Goosby, M.D.
U.S. Global AIDS Coordinator

AIDS 2012 - Turning the Tide Together
The Global Burden of TB - 2010

PEPFAR

Estimated number of cases

All forms of TB 8.8 million (range: 8.5–9.2 million)

HIV-associated TB 1.1 million (13%) (range: 1.0–1.2 million)

Multidrug-resistant TB (MDR-TB) 440,000 (range: 390,000–510,000)

Estimated number of deaths

1.45 million (range: 1.2–1.6 million)

350,000 (range: 320,000–390,000)

about 150,000

The Global Burden of TB - 2010

Estimated TB incidence rates, by country, 2010

TB cases per 100,000

0–24

25–49

50–99

100–299

>=300

No estimate
Why is TB/HIV a priority for PEPFAR?

- 79% of all TB/HIV cases worldwide are in Africa
- 50% of all TB/HIV cases worldwide are in just 9 Africa countries
- 23% of all HIV-related deaths are due to TB.
- PEPFAR-supported programs as an essential platform to address TB/HIV
- PEPFAR model of working with national TB and AIDS programs, diverse partners and multilaterals
What is PEPFAR doing in TB/HIV?

- More than 13,500 HIV care and treatment sites, including 5,200 providing ART.
- In 2011:
  - 3.9 million PLWH were screened for TB in HIV care or treatment settings.
  - 230,000 PLWH in care started TB treatment
- PEPFAR funding for TB/HIV programs has increased more than 800% over five years
Xpert MTB/RIF: A Revolution in TB Diagnosis

- Supporting price reduction to $9.98 per cartridge (with USAID, BMGF, & Unitaid)
- 136 instruments in 2011
- >100 instruments planned
- Implementation TA
- Evaluation

Smart investment:
“*Our analysis showed that Xpert was cost-effective at reducing early mortality during the first 6 months of ART compared with the current practice.*” (Abimbola et al, JAIDS, 2012)
Coverage of cotrimoxazole and ART among HIV positive TB patients in PEPFAR and non-PEPFAR funded countries in the WHO African Region 2003 - 2010

PEPFAR countries reported in African Region (WHO): Angola, Botswana, Cote d'Ivoire, Democratic republic of the Congo, Ethiopia, Ghana, Kenya, Lesotho, Malawi, Mozambique, Namibia, Nigeria, South Africa, Swaziland, Tanzania, Uganda, Zambia, Zimbabwe

Non-Pepfar countries reported: Burkina Faso, Burundi, Central African Republic, Congo, Equatorial Guinea, Gambia, Guinea, Guinea-Bissau, Liberia, Madagascar, Mali, Mauritania, Mauritius, Sao Tome and Principe, Senegal, Seychelles, Sierra Leone

Source: WHO
New Presidential Targets for HIV/AIDS

- **Antiretroviral Treatment**: 6 Million People on ART by End of 2013
- **PMTCT**: 1.5 Million Additional HIV+ Pregnant Women on ART or Prophylaxis by End of 2013
- **Male Circumcision**: 4.7 Million Additional VMMCs by End of 2013
Societal Benefits of ART

Scaling ART Positively Impacts Whole Communities

- For every 1000 patient-years of treatment:
  - 228 patient deaths averted
  - 449 children not orphaned
  - 61 sexual transmissions of HIV averted
  - 26 vertical (mother-to-child) infections averted
  - 9 TB cases averted among HIV patients
  - 2.2 life-years gained
ART Reduces Mortality and Prevents TB Incidence

ART prevents TB incidence

Early ART reduces mortality
What must we do more of going forward? What must we do better?

• AIDS-Free Generation Emphasis Areas for TB/HIV:
  – Ending HIV associated TB among PLHIV with massive coverage of ART, IPT and infection control
  – Ramping up of ART in TB clinics.
  – TB screening and diagnosis in ANC and PMTCT settings
  – HIV testing: TB patients’ family members, TB suspects;
  – PHDP (positive health, dignity and prevention)

• Greater collaboration between TB and HIV communities

• HIV programs taking greater responsibility for the implementation of TB/HIV collaborative activities

• Increasing engagement with civil society for expertise and greater reach
Next Steps

- There is global consensus that controversies around TB/HIV are largely resolved

- Gaps in policy and guidance are resolved

- *Focus now should be on scaling up and catalyzing implementation*
Thank You

For further information, please visit:

www.PEPFAR.gov
www.facebook.com/PEPFAR
www.twitter.com/PEPFAR